Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805

NCT01424540 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: GSK2336805 150mg
OTHER: Placebo

Sponsor

GlaxoSmithKline